AstraZeneca and Neurimmune close deal for NI006
01 March 2022 07:00 GMT AstraZeneca and Neurimmune close exclusive global collaboration and licence agreement to develop and commercialise NI006 Alexion, AstraZeneca's Rare Disease group, has closed an exclusive global collaboration and licence agreement with Neurimmune AG for NI006, an investigational human monoclonal antibody currently in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), an underdiagnosed, systemic